Relugolix
- Generic Name
- Relugolix
- Brand Names
- Myfembree, Orgovyx
- Drug Type
- Small Molecule
- Chemical Formula
- C29H27F2N7O5S
- CAS Number
- 737789-87-6
- Unique Ingredient Identifier
- P76B05O5V6
- Background
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment ...
- Indication
适用于治疗成年晚期前列腺癌症患者。
- Associated Conditions
- Advanced Hormone Sensitive Prostate Cancer, Advanced Prostate Cancer, Heavy Menstrual Bleeding, Severe Pain
- Associated Therapies
- -
A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT02083185
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath